Advertisement


Giorgio V. Scagliotti, MD, PhD, on ALK-Rearranged NSCLC: Results From the ASCEND-5 Trial

2016 ESMO Congress

Advertisement

Giorgio V. Scagliotti, MD, PhD, of the University of Torino, discusses study findings on ceritinib vs chemotherapy in patients with advanced ALK-rearranged non-small cell lung cancer previously treated with chemotherapy and crizotinib. (Abstract LBA42)



Related Videos

Genomics/Genetics
Solid Tumors

Janessa J. Laskin, MD, on Tumor Gene Expression and Advanced Cancers

Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients ...

Lung Cancer

Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024 (German Language Version)

Martin Reck, MD, PhD, of the LungenClinic, discusses in German study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung ca...

Prostate Cancer

Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermedia...

Multiple Myeloma

Katja Weisel, MD, on Multiple Myeloma: Results of the CASTOR Study (German Language Version)

Katja Weisel, MD, of the University of Tübingen, discusses in German study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with rela...

Lung Cancer

Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial

Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses phase III findings on a comparison of atezolizumab with docetaxel in pat...

Advertisement

Advertisement



Advertisement